 <h1>Lopinavir / ritonavir Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2>In Summary</h2><p><b>Commonly reported side effects of lopinavir/ritonavir include:</b> increased serum cholesterol and increased serum triglycerides. <b>Other side effects include:</b> hyperglycemia and increased serum amylase.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to lopinavir/ritonavir: oral solution, oral tablet</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, lopinavir / ritonavir may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking lopinavir / ritonavir:</p><p>
<i>Less common</i>
</p><ul>
<li>Bloating</li>
<li>blurred vision</li>
<li>chills</li>
<li>constipation</li>
<li>darkened urine</li>
<li>dry mouth</li>
<li>fast heartbeat</li>
<li>fever</li>
<li>flushed, dry skin</li>
<li>fruit-like breath odor</li>
<li>increased hunger</li>
<li>increased thirst</li>
<li>increased urination</li>
<li>indigestion</li>
<li>loss of appetite</li>
<li>loss of consciousness</li>
<li>nausea</li>
<li>pains in the stomach, side, or abdomen, possibly moving to the back</li>
<li>sweating</li>
<li>troubled breathing</li>
<li>unexplained weight loss</li>
<li>vomiting</li>
<li>yellow eyes or skin</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Blistering, peeling, or loosening of the skin</li>
<li>chest pain or discomfort</li>
<li>cough</li>
<li>diarrhea</li>
<li>itching</li>
<li>joint or muscle pain</li>
<li>lightheadedness, dizziness, or fainting</li>
<li>red skin lesions, often with a purple center</li>
<li>red, irritated eyes</li>
<li>slow or irregular heartbeat</li>
<li>sore throat</li>
<li>sores, ulcers, or white spots in the mouth or on the lips</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<i>Get emergency help immediately if any of the following symptoms of overdose occur while taking lopinavir / ritonavir:</i>
</p><p>
<i>Symptoms of overdose</i>
</p><ul>
<li>Agitation</li>
<li>confusion</li>
<li>cool, sweaty skin</li>
<li>decreased appetite</li>
<li>decreased awareness or responsiveness</li>
<li>decreased urine output</li>
<li>depression</li>
<li>fast, irregular, or pounding heartbeat</li>
<li>fast, shallow breathing</li>
<li>general feeling of discomfort</li>
<li>headache</li>
<li>hostility</li>
<li>irritability</li>
<li>muscle pain or cramping</li>
<li>muscle twitching</li>
<li>pounding, slow heartbeat</li>
<li>rapid weight gain</li>
<li>seizures</li>
<li>severe sleepiness</li>
<li>stomach discomfort</li>
<li>swelling of the face, ankles, or hands</li>
<li>swelling of the feet or lower legs</li>
<li>unusual drowsiness, dullness, tiredness, weakness, or feeling of sluggishness</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of lopinavir / ritonavir may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>Less common</i>
</p><ul>
<li>Abnormal stools</li>
<li>belching</li>
<li>heartburn</li>
<li>lack or loss of strength</li>
<li>pain</li>
<li>skin rash</li>
<li>trouble with sleeping</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Redistribution of body fat</li>
</ul><p>
<!-- end oral solution, oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to lopinavir / ritonavir: oral capsule, oral liquid, oral tablet</i></p><h3>General</h3><p>In clinical studies, this drug was used with nucleoside reverse transcriptase inhibitors with or without efavirenz or nevirapine.  The most common side effects were diarrhea, nausea, vomiting, hypertriglyceridemia, and hypercholesterolemia.  Diarrhea, nausea, and vomiting occurred more often at the start of therapy while hypertriglyceridemia and hypercholesterolemia generally occurred later.  Diarrhea was reported more often when this drug was used once a day than when it was used twice a day.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (up to 19.5%), nausea (up to 10.3%)</p>
<p><b>Common</b> (1% to 10%): Increased amylase, vomiting, abdominal pain (upper and lower), increased lipase, gastroenteritis and colitis, dyspepsia, pancreatitis, gastroesophageal reflux disease, hemorrhoids, flatulence, abdominal distention, constipation</p>
<p><b>Uncommon</b> (0.1% to 1%): Stomatitis and oral ulcers, duodenitis, gastritis, gastrointestinal hemorrhage (including rectal hemorrhage), dry mouth, gastrointestinal ulcer, fecal incontinence</p>
<p><b>Frequency not reported</b>: Abnormal feces, dysphagia, abdominal discomfort, enteritis, enterocolitis, eructation, esophagitis, gastric disorder, gastric ulcer, hemorrhagic enterocolitis, mouth ulceration, periodontitis, sialadenitis, stomach discomfort, ulcerative stomatitis<sup>[Ref]</sup></p><p>Increased amylase and lipase, greater than 2 times the upper limit of normal (2 x ULN), were reported in up to 8% and up to 5% of patients, respectively.</p>
<p></p>
<p>Pancreatitis, including fatalities, has occurred in patients receiving this drug, including those who developed hypertriglyceridemia.  Although a causal relationship has not been established, marked triglyceride elevation is a risk factor for the development of pancreatitis.<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Increased total cholesterol (up to 39%), increased triglycerides (up to 36%)</p>
<p><b>Common</b> (1% to 10%): Hypercholesterolemia, hypertriglyceridemia, increased glucose, increased uric acid, decreased weight, decreased appetite, decreased inorganic phosphorus, blood glucose disorders (including diabetes mellitus)</p>
<p><b>Uncommon</b> (0.1% to 1%): Lactic acidosis, increased appetite, anorexia</p>
<p><b>Frequency not reported</b>: Avitaminosis, hypovitaminosis, dehydration, dyslipidemia, hyperamylasemia, hyperlipasemia, decreased glucose tolerance, lipomatosis, obesity, hyperglycemia, new onset diabetes mellitus, exacerbation of preexisting diabetes mellitus, ketoacidosis, insulin resistance, hyperlactatemia</p>
<p><b>Postmarketing reports</b>: Redistribution/accumulation of body fat (including central obesity, dorsocervical fat enlargement, peripheral wasting, facial wasting, breast enlargement, "cushingoid appearance")<sup>[Ref]</sup></p><p>Increased total cholesterol (greater than 300 mg/dL), triglycerides (greater than 750 mg/dL), glucose (greater than 250 mg/dL), and uric acid (greater than 12 mg/dL) have been reported in up to 39%, up to 36%, up to 5%, and up to 5% of patients, respectively.  Decreased inorganic phosphorus (less than 1.5 mg/dL) has been reported in up to 2% of patients.</p>
<p></p>
<p>Episodes of hyperglycemia, new onset diabetes mellitus, and exacerbation of preexisting diabetes mellitus have been reported during postmarketing studies in HIV-infected patients receiving protease inhibitors.  In some cases, diabetic ketoacidosis has occurred.  No causal relationship has been established.<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Increased GGT (up to 29%), increased ALT (up to 11%)</p>
<p><b>Common</b> (1% to 10%): Increased AST, hepatitis (including increased AST, ALT, GGT), increased total bilirubin</p>
<p><b>Uncommon</b> (0.1% to 1%): Hepatomegaly, cholangitis, hepatic steatosis, hyperbilirubinemia</p>
<p><b>Frequency not reported</b>: Fatty liver deposit, cytolytic hepatitis, liver tenderness, hepatic failure, cholecystitis, hepatic dysfunction</p>
<p><b>Postmarketing reports</b>: Jaundice<sup>[Ref]</sup></p><p>Increased GGT (greater than 300 units/L), ALT (greater than 215 units/L), AST (greater than 180 units/L), and total bilirubin (greater than 3.48 mg/dL) have been reported in up to 29%, up to 11%, up to 10%, and 1% of patients, respectively.</p>
<p></p>
<p>Patients with underlying hepatitis B or C or marked elevations in transaminases before initiation of therapy may be at an increased risk for developing further transaminase elevations or liver decompensation.  There have been reports of hepatic dysfunction with some cases leading to death.  A causal relationship with this drug has not been proven since these cases have generally occurred in patients with advanced HIV who also had underlying chronic hepatitis or cirrhosis and were taking multiple concomitant medications.<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Upper respiratory tract infection (up to 13.9%)</p>
<p><b>Common</b> (1% to 10%): Lower respiratory tract infection</p>
<p><b>Frequency not reported</b>: Bronchitis, asthma, bronchopneumonia, dyspnea, pulmonary edema, pharyngitis, rhinitis, increased cough, sinusitis, influenza<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Fatigue (including asthenia)</p>
<p><b>Uncommon</b> (0.1% to 1%): Increased weight</p>
<p><b>Frequency not reported</b>: Pyrexia, chills, pain, generalized pain, back and abdomen enlargement, chest pain, cyst, edema, peripheral edema, face edema, influenza syndrome, hypertrophy, malaise, drug interaction, increased drug level, infection (bacterial, viral), otitis media, breast enlargement<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Musculoskeletal pain (including arthralgia, back pain), increased creatine phosphokinase, myalgia, muscle disorders (such as weakness, spasms)</p>
<p><b>Uncommon</b> (0.1% to 1%): Rhabdomyolysis, osteonecrosis</p>
<p><b>Frequency not reported</b>: Arthropathy, arthrosis, muscular weakness, joint disorder, osteoarthritis, extremity pain, myasthenia, myositis, perineal abscess<sup>[Ref]</sup></p><p>Increased creatine phosphokinase (greater than 4 x ULN) was reported in up to 5% of patients.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache (including migraine), neuropathy (including peripheral neuropathy), dizziness</p>
<p><b>Uncommon</b> (0.1% to 1%): Ageusia, convulsion, vertigo, tremor, cerebrovascular accident/event, tinnitus, dysgeusia, paresthesia</p>
<p><b>Frequency not reported</b>: Amnesia, ataxia, balance disorder, abnormal coordination, cerebral infarction, dyskinesia, encephalopathy, facial paralysis/palsy, hypertonia, peripheral neuritis, somnolence, hyperacusis, extrapyramidal disorder<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Decreased neutrophils (less than 0.75 x 10[9]/L) and hemoglobin (less than 8 g/dL) have been reported in up to 5% and up to 2% of patients, respectively.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Decreased neutrophils, anemia, decreased hemoglobin, leukopenia, neutropenia, lymphadenopathy</p>
<p><b>Rare</b> (less than 0.1%): Hemolytic anemia, spontaneous bleeding in hemophiliacs</p>
<p><b>Frequency not reported</b>: Splenomegaly<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Anxiety, insomnia</p>
<p><b>Uncommon</b> (0.1% to 1%): Abnormal dreams, decreased libido, depression</p>
<p><b>Frequency not reported</b>: Affect lability, agitation, apathy, confusional state, disorientation, mood swings, nervousness, abnormal thinking<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Rash (including maculopapular rash), skin infections (including cellulitis, folliculitis, furuncle), acquired lipodystrophy (including facial wasting), dermatitis/rash (including eczema, seborrheic dermatitis), night sweats, pruritus</p>
<p><b>Uncommon</b> (0.1% to 1%): Alopecia, capillaritis, vasculitis</p>
<p><b>Frequency not reported</b>: Acne, dry skin, acneiform dermatitis, allergic dermatitis, exfoliative dermatitis, idiopathic capillaritis, generalized rash, nail disorder, seborrhea, benign skin neoplasm, skin discoloration, skin hypertrophy, skin ulcer, skin striae, swelling face, hyperhidrosis, acute generalized exanthematous pustulosis</p>
<p><b>Postmarketing reports</b>: Toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Common</b> (1% to 10%): Decreased calculated CrCl, renal failure</p>
<p><b>Uncommon</b> (0.1% to 1%): Nephritis</p>
<p><b>Frequency not reported</b>: Nephrolithiasis, renal disorder<sup>[Ref]</sup></p><p>Decreased calculated CrCl (less than 50 mL/min) was reported in up to 3% of patients.<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Hypersensitivity (including urticaria, angioedema)</p>
<p><b>Frequency not reported</b>: Drug hypersensitivity, severe skin and mucous hypersensitivity reaction with transient multiorgan failure<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Hypertension</p>
<p><b>Uncommon</b> (0.1% to 1%): Deep vein thrombosis, atherosclerosis (such as myocardial infarction), atrioventricular (AV) block, tricuspid valve incompetence</p>
<p><b>Frequency not reported</b>: Distended veins, angina pectoris, atrial fibrillation, chest pain, palpitation, orthostatic hypotension, thrombophlebitis, varicose vein, vasculitis, sinus arrest, bradycardia-tachycardia syndrome, vasodilatation</p>
<p><b>Postmarketing reports</b>: Bradyarrhythmias, first-degree AV block, second-degree AV block, third-degree AV block, QTc interval prolongation, torsades de pointes<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Erectile dysfunction, menstrual disorders (amenorrhea, menorrhagia)</p>
<p><b>Uncommon</b> (0.1% to 1%): Hematuria</p>
<p><b>Frequency not reported</b>: Ejaculation disorder, impotence, abnormal urine odor, urine abnormality<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Uncommon</b> (0.1% to 1%): Visual impairment</p>
<p><b>Frequency not reported</b>: Visual disturbance, eye disorder<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Uncommon</b> (0.1% to 1%): Immune reconstitution/reactivation syndrome</p>
<p><b>Frequency not reported</b>: Autoimmune disorders in the setting of immune reconstitution (e.g., Graves' disease, polymyositis, Guillain-Barre syndrome)</p><h3>Endocrine</h3><p><b>Uncommon</b> (0.1% to 1%): Hypogonadism</p>
<p><b>Frequency not reported</b>: Cushing's syndrome, hypothyroidism, gynecomastia<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Frequency not reported</b>: Neoplasm, lipoma</p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cvetkovic R,  Goa K "Lopinavir/Ritonavir : A Review of its Use in the Management of HIV Infection." Drugs 63 (2003): 769-802</p><p id="ref_2">2. Eron J Jr,  Yeni P,  Gathe J Jr, et al. "The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial." Lancet 368 (2006): 476-82</p><p id="ref_3">3. Hicks C,  King MS,  Gulick RM, et al. "Long-term safety and durable antiretroviral activity of lopinavir / ritonavir in treatment-naive patients: 4 year follow-up study." AIDS 18 (2004): 775-779</p><p id="ref_4">4. Mangum EM,  Graham KK "Lopinavir-Ritonavir: a new protease inhibitor." Pharmacotherapy 21 (2001): 1352-63</p><p id="ref_5">5. AIDSinfo. NIH. National Institutes of Health "Guidelines for the use of antiretroviral agents in pediatric HIV infection. Available from: URL: http://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatricguidelines.pdf."   ([2015 Mar 5]):</p><p id="ref_6">6. Leon A,  Martinez E,  Sarasa M, et al. "Impact of steady-state lopinavir plasma levels on plasma lipids and body composition after 24 weeks of lopinavir / ritonavir-containing therapy free of thymidine analogues." J Antimicrob Chemother  (2007):</p><p id="ref_7">7. HHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Office of AIDS Research Advisory Council (OARAC). NIH. National Institutes of Health "Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available from: URL: http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf."   ([2014 May]):</p><p id="ref_8">8. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_9">9. Corbett AH,  Lim ML,  Kashuba AD "Kaletra (Lopinavir/Ritonavir)." Ann Pharmacother 36 (2002): 1193-1203</p><p id="ref_10">10. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_11">11. Eron JJ,  Feinberg J,  Kessler HA, et al. "Once-Daily versus Twice-Daily Lopinavir/Ritonavir in Antiretroviral-Naive HIV-Positive Patients: A 48-Week Randomized Clinical Trial." J Infect Dis 189 (2004): 265-72</p><p id="ref_12">12. "Product Information. Kaletra (lopinavir-ritonavir)" Abbott Pharmaceutical, Abbott Park, IL. </p><p id="ref_13">13. "Drugs for HIV infection." Med Lett Drugs Ther 43 (2001): 103-8</p><p id="ref_14">14. Warnke D,  Barreto J,  Temesgen Z "Antiretroviral drugs." J Clin Pharmacol 47 (2007): 1570-9</p><p id="ref_15">15. Borras-Blasco J,  Belda A,  Rosique-Robles D,  Castera E,  Abad J,  Amoros-Quiles I "Hair loss induced by lopinavir-ritonavir." Pharmacotherapy 27 (2007): 1215-8</p><p id="ref_16">16. Oldfield V,  Plosker GL "Lopinavir/Ritonavir : A Review of its Use in the Management of HIV Infection." Drugs 66 (2006): 1275-1299</p><p id="ref_17">17. Guest JL,  Ruffin C,  Tschampa JM,  DeSilva KE,  Rimland D "Differences in rates of diarrhea in patients with human immunodeficiency virus receiving lopinavir-ritonavir or nelfinavir." Pharmacotherapy 24 (2004): 727-35</p><p id="ref_18">18. "FDA approves new protease inhibitor for HIV infection." Am J Health Syst Pharm 57 (2000): 1942</p><p id="ref_19">19. Brennan-Benson P,  Pakianathan M,  Rice P, et al. "Enfurvitide prevents vertical transmission of multidrug-resistant HIV-1 in pregnancy but does not cross the placenta." AIDS 20 (2006): 297-9</p><p id="ref_20">20. Voigt E,  Wasmuth JC,  Vogel M, et al. "Safety, Efficacy and Development of Resistance under the New Protease Inhibitor Lopinavir/Ritonavir: 48-Week Results." Infection 32 (2004): 82-8</p><p id="ref_21">21. Rabaud C,  Burty C,  Grandidier M, et al. "Tolerability of postexposure prophylaxis with the combination of zidovudine-lamivudine and lopinavir-ritonavir for HIV infection." Clin Infect Dis 40 (2005): 303-5</p><p id="ref_22">22. Johnson M,  Grinsztejn B,  Rodriguez C, et al. "Atazanavir plus ritonavir or saquinavir, and lopinavir / ritonavir in patients experiencing multiple virological failures." AIDS 19 (2005): 685-94</p><p id="ref_23">23. Hammer SM,  Saag MS,  Schechter M, et al. "Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel." JAMA 296 (2006): 827-43</p><p id="ref_24">24. Borras-Blasco J,  Navarro-Ruiz A,  Borras C,  Castera E "Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection." J Antimicrob Chemother 62 (2008): 879-88</p><p id="ref_25">25. Roberts DM,  Ray JE,  Buckley NA "Mild clinical toxicity and dose-dependent pharmacokinetics following acute lopinavir / ritonavir poisoning in a HIV-positive patient." AIDS 22 (2008): 792-3</p><p id="ref_26">26. Johnson M,  Grinsztejn B,  Rodriguez C, et al. "96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir / ritonavir in patients with multiple virologic failures." AIDS 20 (2006): 711-718</p><p id="ref_27">27. Piacenti FJ "An update and review of antiretroviral therapy." Pharmacotherapy 26 (2006): 1111-33</p><p id="ref_28">28. Henney JE "New drug for HIV infection." JAMA 284 (2000): 2178</p><p id="ref_29">29. Anderson PL "Pharmacologic perspectives for once-daily antiretroviral therapy." Ann Pharmacother 38 (2004): 1969-70</p><p id="ref_30">30. "Drugs for HIV infection." Treat Guidel Med Lett 7 (2009): 11-22</p><p id="ref_31">31. Martinez E,  Domingo P,  Galindo MJ, et al. "Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir." Clin Infect Dis 38 (2004): 1017-23</p><p id="ref_32">32. Cameron DW,  Becker S,  King MS, et al. "Exploratory study comparing the metabolic toxicities of a lopinavir / ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir / ritonavir plus zidovudine/lamivudine nucleoside regimen." J Antimicrob Chemother 59 (2007): 957-63</p><p id="ref_33">33. Molto J,  Santos JR,  Negredo E,  Miranda C,  Videla S,  Clotet B "Lopinavir / ritonavir monotherapy as a simplification strategy in routine clinical practice." J Antimicrob Chemother 60 (2007): 436-9</p><p id="ref_34">34. Doco-Lecompte T,  Garrec A,  Thomas L,  Trechot P,  May T,  Rabaud C "Lopinavir-ritonavir (Kaletra) and lithiasis: seven cases." AIDS 18 (2004): 705-6</p><p id="ref_35">35. Bergersen BM "Cardiovascular Risk in Patients with HIV Infection : Impact of Antiretroviral Therapy." Drugs 66 (2006): 1971-87</p><p id="ref_36">36. Bongiovanni M,  Bini T,  Tordato F, et al. "Immunovirological outcomes in 70 HIV-1-infected patients who switched to lopinavir / ritonavir after failing at least one protease inhibitor-containing regimen: a retrospective cohort study." J Antimicrob Chemother 51 (2003): 171-4</p><p id="ref_37">37. Badiou S,  De Boever CM,  Dupuy AM,  Baillat V,  Cristol JP,  Reynes J "Small dense LDL and atherogenic lipid profile in HIV-positive adults: influence of lopinavir / ritonavir-containing regimen." AIDS 17 (2003): 772-4</p><p id="ref_38">38. Fischl MA,  Collier AC,  Mukherjee AL, et al. "Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen." AIDS 21 (2007): 325-333</p><p id="ref_39">39. Soriano V,  Puoti M,  Sulkowski M, et al. "Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel." AIDS 21 (2007): 1073-89</p><p id="ref_40">40. Canta F,  Marrone R,  Bonora S, et al. "Pharmacokinetics and hepatotoxicity of lopinavir / ritonavir in non-cirrhotic HIV and hepatitis C virus (HCV) co-infected patients." J Antimicrob Chemother  (2005):</p><p id="ref_41">41. Manfredi R,  Sabbatani S "Serious, multi-organ hypersensitivity to lopinavir alone, involving cutaneous-mucous rash, and myeloid, liver, and kidney function." AIDS 20 (2006): 2399-2400</p><p id="ref_42">42. Yazdanpanah Y,  Viget N,  Cheret A, et al. "Increased bleeding in HIV-positive haemophiliac patients treated with lopinavir-ritonavir." AIDS 17 (2003): 2397-9</p><p id="ref_43">43. Ghosn J,  Duvivier C,  Tubiana R,  Katlama C,  Caumes E "Acute generalized exanthematous pustulosis induced by HIV postexposure prophylaxis with lopinavir-ritonavir." Clin Infect Dis 41 (2005): 1360-1</p><p id="ref_44">44. Yotsumoto M,  Kitano K,  Saito H "Bradycardia-tachycardia syndrome induced by lopinavir-ritonavir in a patient with AIDS." AIDS 19 (2005): 1547-8</p><p id="ref_45">45. Worm SW,  Sabin C,  Weber R, et al. "Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study." J Infect Dis 201 (2009): 318-30</p><p id="ref_46">46. Calza L,  Manfredi R,  Verucchi G "Myocardial infarction risk in HIV-infected patients: epidemiology, pathogenesis,  and clinical management." AIDS 24 (2010): 789-802</p></div>
<div class="more-resources" id="moreResources">
<h2>More about lopinavir / ritonavir</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>4 Reviews</li>
<li>Drug class: protease inhibitors</li>
<li>FDA Alerts (2)</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Lopinavir and ritonavir &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Kaletra</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +2 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>HIV Infection</li>
<li>Nonoccupational Exposure</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to lopinavir / ritonavir: oral capsule, oral liquid, oral tablet</i></p><h3>General</h3><p>In clinical studies, this drug was used with nucleoside reverse transcriptase inhibitors with or without efavirenz or nevirapine.  The most common side effects were diarrhea, nausea, vomiting, hypertriglyceridemia, and hypercholesterolemia.  Diarrhea, nausea, and vomiting occurred more often at the start of therapy while hypertriglyceridemia and hypercholesterolemia generally occurred later.  Diarrhea was reported more often when this drug was used once a day than when it was used twice a day.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (up to 19.5%), nausea (up to 10.3%)</p><p><b>Common</b> (1% to 10%): Increased amylase, vomiting, abdominal pain (upper and lower), increased lipase, gastroenteritis and colitis, dyspepsia, pancreatitis, gastroesophageal reflux disease, hemorrhoids, flatulence, abdominal distention, constipation</p><p><b>Uncommon</b> (0.1% to 1%): Stomatitis and oral ulcers, duodenitis, gastritis, gastrointestinal hemorrhage (including rectal hemorrhage), dry mouth, gastrointestinal ulcer, fecal incontinence</p><p><b>Frequency not reported</b>: Abnormal feces, dysphagia, abdominal discomfort, enteritis, enterocolitis, eructation, esophagitis, gastric disorder, gastric ulcer, hemorrhagic enterocolitis, mouth ulceration, periodontitis, sialadenitis, stomach discomfort, ulcerative stomatitis<sup>[Ref]</sup></p><p>Increased amylase and lipase, greater than 2 times the upper limit of normal (2 x ULN), were reported in up to 8% and up to 5% of patients, respectively.</p><p></p><p>Pancreatitis, including fatalities, has occurred in patients receiving this drug, including those who developed hypertriglyceridemia.  Although a causal relationship has not been established, marked triglyceride elevation is a risk factor for the development of pancreatitis.<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Increased total cholesterol (up to 39%), increased triglycerides (up to 36%)</p><p><b>Common</b> (1% to 10%): Hypercholesterolemia, hypertriglyceridemia, increased glucose, increased uric acid, decreased weight, decreased appetite, decreased inorganic phosphorus, blood glucose disorders (including diabetes mellitus)</p><p><b>Uncommon</b> (0.1% to 1%): Lactic acidosis, increased appetite, anorexia</p><p><b>Frequency not reported</b>: Avitaminosis, hypovitaminosis, dehydration, dyslipidemia, hyperamylasemia, hyperlipasemia, decreased glucose tolerance, lipomatosis, obesity, hyperglycemia, new onset diabetes mellitus, exacerbation of preexisting diabetes mellitus, ketoacidosis, insulin resistance, hyperlactatemia</p><p><b>Postmarketing reports</b>: Redistribution/accumulation of body fat (including central obesity, dorsocervical fat enlargement, peripheral wasting, facial wasting, breast enlargement, "cushingoid appearance")<sup>[Ref]</sup></p><p>Increased total cholesterol (greater than 300 mg/dL), triglycerides (greater than 750 mg/dL), glucose (greater than 250 mg/dL), and uric acid (greater than 12 mg/dL) have been reported in up to 39%, up to 36%, up to 5%, and up to 5% of patients, respectively.  Decreased inorganic phosphorus (less than 1.5 mg/dL) has been reported in up to 2% of patients.</p><p></p><p>Episodes of hyperglycemia, new onset diabetes mellitus, and exacerbation of preexisting diabetes mellitus have been reported during postmarketing studies in HIV-infected patients receiving protease inhibitors.  In some cases, diabetic ketoacidosis has occurred.  No causal relationship has been established.<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Increased GGT (up to 29%), increased ALT (up to 11%)</p><p><b>Common</b> (1% to 10%): Increased AST, hepatitis (including increased AST, ALT, GGT), increased total bilirubin</p><p><b>Uncommon</b> (0.1% to 1%): Hepatomegaly, cholangitis, hepatic steatosis, hyperbilirubinemia</p><p><b>Frequency not reported</b>: Fatty liver deposit, cytolytic hepatitis, liver tenderness, hepatic failure, cholecystitis, hepatic dysfunction</p><p><b>Postmarketing reports</b>: Jaundice<sup>[Ref]</sup></p><p>Increased GGT (greater than 300 units/L), ALT (greater than 215 units/L), AST (greater than 180 units/L), and total bilirubin (greater than 3.48 mg/dL) have been reported in up to 29%, up to 11%, up to 10%, and 1% of patients, respectively.</p><p></p><p>Patients with underlying hepatitis B or C or marked elevations in transaminases before initiation of therapy may be at an increased risk for developing further transaminase elevations or liver decompensation.  There have been reports of hepatic dysfunction with some cases leading to death.  A causal relationship with this drug has not been proven since these cases have generally occurred in patients with advanced HIV who also had underlying chronic hepatitis or cirrhosis and were taking multiple concomitant medications.<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Upper respiratory tract infection (up to 13.9%)</p><p><b>Common</b> (1% to 10%): Lower respiratory tract infection</p><p><b>Frequency not reported</b>: Bronchitis, asthma, bronchopneumonia, dyspnea, pulmonary edema, pharyngitis, rhinitis, increased cough, sinusitis, influenza<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Fatigue (including asthenia)</p><p><b>Uncommon</b> (0.1% to 1%): Increased weight</p><p><b>Frequency not reported</b>: Pyrexia, chills, pain, generalized pain, back and abdomen enlargement, chest pain, cyst, edema, peripheral edema, face edema, influenza syndrome, hypertrophy, malaise, drug interaction, increased drug level, infection (bacterial, viral), otitis media, breast enlargement<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Musculoskeletal pain (including arthralgia, back pain), increased creatine phosphokinase, myalgia, muscle disorders (such as weakness, spasms)</p><p><b>Uncommon</b> (0.1% to 1%): Rhabdomyolysis, osteonecrosis</p><p><b>Frequency not reported</b>: Arthropathy, arthrosis, muscular weakness, joint disorder, osteoarthritis, extremity pain, myasthenia, myositis, perineal abscess<sup>[Ref]</sup></p><p>Increased creatine phosphokinase (greater than 4 x ULN) was reported in up to 5% of patients.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache (including migraine), neuropathy (including peripheral neuropathy), dizziness</p><p><b>Uncommon</b> (0.1% to 1%): Ageusia, convulsion, vertigo, tremor, cerebrovascular accident/event, tinnitus, dysgeusia, paresthesia</p><p><b>Frequency not reported</b>: Amnesia, ataxia, balance disorder, abnormal coordination, cerebral infarction, dyskinesia, encephalopathy, facial paralysis/palsy, hypertonia, peripheral neuritis, somnolence, hyperacusis, extrapyramidal disorder<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Decreased neutrophils (less than 0.75 x 10[9]/L) and hemoglobin (less than 8 g/dL) have been reported in up to 5% and up to 2% of patients, respectively.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Decreased neutrophils, anemia, decreased hemoglobin, leukopenia, neutropenia, lymphadenopathy</p><p><b>Rare</b> (less than 0.1%): Hemolytic anemia, spontaneous bleeding in hemophiliacs</p><p><b>Frequency not reported</b>: Splenomegaly<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Anxiety, insomnia</p><p><b>Uncommon</b> (0.1% to 1%): Abnormal dreams, decreased libido, depression</p><p><b>Frequency not reported</b>: Affect lability, agitation, apathy, confusional state, disorientation, mood swings, nervousness, abnormal thinking<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Rash (including maculopapular rash), skin infections (including cellulitis, folliculitis, furuncle), acquired lipodystrophy (including facial wasting), dermatitis/rash (including eczema, seborrheic dermatitis), night sweats, pruritus</p><p><b>Uncommon</b> (0.1% to 1%): Alopecia, capillaritis, vasculitis</p><p><b>Frequency not reported</b>: Acne, dry skin, acneiform dermatitis, allergic dermatitis, exfoliative dermatitis, idiopathic capillaritis, generalized rash, nail disorder, seborrhea, benign skin neoplasm, skin discoloration, skin hypertrophy, skin ulcer, skin striae, swelling face, hyperhidrosis, acute generalized exanthematous pustulosis</p><p><b>Postmarketing reports</b>: Toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Common</b> (1% to 10%): Decreased calculated CrCl, renal failure</p><p><b>Uncommon</b> (0.1% to 1%): Nephritis</p><p><b>Frequency not reported</b>: Nephrolithiasis, renal disorder<sup>[Ref]</sup></p><p>Decreased calculated CrCl (less than 50 mL/min) was reported in up to 3% of patients.<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Hypersensitivity (including urticaria, angioedema)</p><p><b>Frequency not reported</b>: Drug hypersensitivity, severe skin and mucous hypersensitivity reaction with transient multiorgan failure<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Hypertension</p><p><b>Uncommon</b> (0.1% to 1%): Deep vein thrombosis, atherosclerosis (such as myocardial infarction), atrioventricular (AV) block, tricuspid valve incompetence</p><p><b>Frequency not reported</b>: Distended veins, angina pectoris, atrial fibrillation, chest pain, palpitation, orthostatic hypotension, thrombophlebitis, varicose vein, vasculitis, sinus arrest, bradycardia-tachycardia syndrome, vasodilatation</p><p><b>Postmarketing reports</b>: Bradyarrhythmias, first-degree AV block, second-degree AV block, third-degree AV block, QTc interval prolongation, torsades de pointes<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Erectile dysfunction, menstrual disorders (amenorrhea, menorrhagia)</p><p><b>Uncommon</b> (0.1% to 1%): Hematuria</p><p><b>Frequency not reported</b>: Ejaculation disorder, impotence, abnormal urine odor, urine abnormality<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Uncommon</b> (0.1% to 1%): Visual impairment</p><p><b>Frequency not reported</b>: Visual disturbance, eye disorder<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Uncommon</b> (0.1% to 1%): Immune reconstitution/reactivation syndrome</p><p><b>Frequency not reported</b>: Autoimmune disorders in the setting of immune reconstitution (e.g., Graves' disease, polymyositis, Guillain-Barre syndrome)</p><h3>Endocrine</h3><p><b>Uncommon</b> (0.1% to 1%): Hypogonadism</p><p><b>Frequency not reported</b>: Cushing's syndrome, hypothyroidism, gynecomastia<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Frequency not reported</b>: Neoplasm, lipoma</p><p id="ref_1">1. Cvetkovic R,  Goa K "Lopinavir/Ritonavir : A Review of its Use in the Management of HIV Infection." Drugs 63 (2003): 769-802</p><p id="ref_2">2. Eron J Jr,  Yeni P,  Gathe J Jr, et al. "The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial." Lancet 368 (2006): 476-82</p><p id="ref_3">3. Hicks C,  King MS,  Gulick RM, et al. "Long-term safety and durable antiretroviral activity of lopinavir / ritonavir in treatment-naive patients: 4 year follow-up study." AIDS 18 (2004): 775-779</p><p id="ref_4">4. Mangum EM,  Graham KK "Lopinavir-Ritonavir: a new protease inhibitor." Pharmacotherapy 21 (2001): 1352-63</p><p id="ref_5">5. AIDSinfo. NIH. National Institutes of Health "Guidelines for the use of antiretroviral agents in pediatric HIV infection. Available from: URL: http://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatricguidelines.pdf."   ([2015 Mar 5]):</p><p id="ref_6">6. Leon A,  Martinez E,  Sarasa M, et al. "Impact of steady-state lopinavir plasma levels on plasma lipids and body composition after 24 weeks of lopinavir / ritonavir-containing therapy free of thymidine analogues." J Antimicrob Chemother  (2007):</p><p id="ref_7">7. HHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Office of AIDS Research Advisory Council (OARAC). NIH. National Institutes of Health "Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available from: URL: http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf."   ([2014 May]):</p><p id="ref_8">8. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_9">9. Corbett AH,  Lim ML,  Kashuba AD "Kaletra (Lopinavir/Ritonavir)." Ann Pharmacother 36 (2002): 1193-1203</p><p id="ref_10">10. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_11">11. Eron JJ,  Feinberg J,  Kessler HA, et al. "Once-Daily versus Twice-Daily Lopinavir/Ritonavir in Antiretroviral-Naive HIV-Positive Patients: A 48-Week Randomized Clinical Trial." J Infect Dis 189 (2004): 265-72</p><p id="ref_12">12. "Product Information. Kaletra (lopinavir-ritonavir)" Abbott Pharmaceutical, Abbott Park, IL. </p><p id="ref_13">13. "Drugs for HIV infection." Med Lett Drugs Ther 43 (2001): 103-8</p><p id="ref_14">14. Warnke D,  Barreto J,  Temesgen Z "Antiretroviral drugs." J Clin Pharmacol 47 (2007): 1570-9</p><p id="ref_15">15. Borras-Blasco J,  Belda A,  Rosique-Robles D,  Castera E,  Abad J,  Amoros-Quiles I "Hair loss induced by lopinavir-ritonavir." Pharmacotherapy 27 (2007): 1215-8</p><p id="ref_16">16. Oldfield V,  Plosker GL "Lopinavir/Ritonavir : A Review of its Use in the Management of HIV Infection." Drugs 66 (2006): 1275-1299</p><p id="ref_17">17. Guest JL,  Ruffin C,  Tschampa JM,  DeSilva KE,  Rimland D "Differences in rates of diarrhea in patients with human immunodeficiency virus receiving lopinavir-ritonavir or nelfinavir." Pharmacotherapy 24 (2004): 727-35</p><p id="ref_18">18. "FDA approves new protease inhibitor for HIV infection." Am J Health Syst Pharm 57 (2000): 1942</p><p id="ref_19">19. Brennan-Benson P,  Pakianathan M,  Rice P, et al. "Enfurvitide prevents vertical transmission of multidrug-resistant HIV-1 in pregnancy but does not cross the placenta." AIDS 20 (2006): 297-9</p><p id="ref_20">20. Voigt E,  Wasmuth JC,  Vogel M, et al. "Safety, Efficacy and Development of Resistance under the New Protease Inhibitor Lopinavir/Ritonavir: 48-Week Results." Infection 32 (2004): 82-8</p><p id="ref_21">21. Rabaud C,  Burty C,  Grandidier M, et al. "Tolerability of postexposure prophylaxis with the combination of zidovudine-lamivudine and lopinavir-ritonavir for HIV infection." Clin Infect Dis 40 (2005): 303-5</p><p id="ref_22">22. Johnson M,  Grinsztejn B,  Rodriguez C, et al. "Atazanavir plus ritonavir or saquinavir, and lopinavir / ritonavir in patients experiencing multiple virological failures." AIDS 19 (2005): 685-94</p><p id="ref_23">23. Hammer SM,  Saag MS,  Schechter M, et al. "Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel." JAMA 296 (2006): 827-43</p><p id="ref_24">24. Borras-Blasco J,  Navarro-Ruiz A,  Borras C,  Castera E "Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection." J Antimicrob Chemother 62 (2008): 879-88</p><p id="ref_25">25. Roberts DM,  Ray JE,  Buckley NA "Mild clinical toxicity and dose-dependent pharmacokinetics following acute lopinavir / ritonavir poisoning in a HIV-positive patient." AIDS 22 (2008): 792-3</p><p id="ref_26">26. Johnson M,  Grinsztejn B,  Rodriguez C, et al. "96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir / ritonavir in patients with multiple virologic failures." AIDS 20 (2006): 711-718</p><p id="ref_27">27. Piacenti FJ "An update and review of antiretroviral therapy." Pharmacotherapy 26 (2006): 1111-33</p><p id="ref_28">28. Henney JE "New drug for HIV infection." JAMA 284 (2000): 2178</p><p id="ref_29">29. Anderson PL "Pharmacologic perspectives for once-daily antiretroviral therapy." Ann Pharmacother 38 (2004): 1969-70</p><p id="ref_30">30. "Drugs for HIV infection." Treat Guidel Med Lett 7 (2009): 11-22</p><p id="ref_31">31. Martinez E,  Domingo P,  Galindo MJ, et al. "Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir." Clin Infect Dis 38 (2004): 1017-23</p><p id="ref_32">32. Cameron DW,  Becker S,  King MS, et al. "Exploratory study comparing the metabolic toxicities of a lopinavir / ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir / ritonavir plus zidovudine/lamivudine nucleoside regimen." J Antimicrob Chemother 59 (2007): 957-63</p><p id="ref_33">33. Molto J,  Santos JR,  Negredo E,  Miranda C,  Videla S,  Clotet B "Lopinavir / ritonavir monotherapy as a simplification strategy in routine clinical practice." J Antimicrob Chemother 60 (2007): 436-9</p><p id="ref_34">34. Doco-Lecompte T,  Garrec A,  Thomas L,  Trechot P,  May T,  Rabaud C "Lopinavir-ritonavir (Kaletra) and lithiasis: seven cases." AIDS 18 (2004): 705-6</p><p id="ref_35">35. Bergersen BM "Cardiovascular Risk in Patients with HIV Infection : Impact of Antiretroviral Therapy." Drugs 66 (2006): 1971-87</p><p id="ref_36">36. Bongiovanni M,  Bini T,  Tordato F, et al. "Immunovirological outcomes in 70 HIV-1-infected patients who switched to lopinavir / ritonavir after failing at least one protease inhibitor-containing regimen: a retrospective cohort study." J Antimicrob Chemother 51 (2003): 171-4</p><p id="ref_37">37. Badiou S,  De Boever CM,  Dupuy AM,  Baillat V,  Cristol JP,  Reynes J "Small dense LDL and atherogenic lipid profile in HIV-positive adults: influence of lopinavir / ritonavir-containing regimen." AIDS 17 (2003): 772-4</p><p id="ref_38">38. Fischl MA,  Collier AC,  Mukherjee AL, et al. "Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen." AIDS 21 (2007): 325-333</p><p id="ref_39">39. Soriano V,  Puoti M,  Sulkowski M, et al. "Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel." AIDS 21 (2007): 1073-89</p><p id="ref_40">40. Canta F,  Marrone R,  Bonora S, et al. "Pharmacokinetics and hepatotoxicity of lopinavir / ritonavir in non-cirrhotic HIV and hepatitis C virus (HCV) co-infected patients." J Antimicrob Chemother  (2005):</p><p id="ref_41">41. Manfredi R,  Sabbatani S "Serious, multi-organ hypersensitivity to lopinavir alone, involving cutaneous-mucous rash, and myeloid, liver, and kidney function." AIDS 20 (2006): 2399-2400</p><p id="ref_42">42. Yazdanpanah Y,  Viget N,  Cheret A, et al. "Increased bleeding in HIV-positive haemophiliac patients treated with lopinavir-ritonavir." AIDS 17 (2003): 2397-9</p><p id="ref_43">43. Ghosn J,  Duvivier C,  Tubiana R,  Katlama C,  Caumes E "Acute generalized exanthematous pustulosis induced by HIV postexposure prophylaxis with lopinavir-ritonavir." Clin Infect Dis 41 (2005): 1360-1</p><p id="ref_44">44. Yotsumoto M,  Kitano K,  Saito H "Bradycardia-tachycardia syndrome induced by lopinavir-ritonavir in a patient with AIDS." AIDS 19 (2005): 1547-8</p><p id="ref_45">45. Worm SW,  Sabin C,  Weber R, et al. "Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study." J Infect Dis 201 (2009): 318-30</p><p id="ref_46">46. Calza L,  Manfredi R,  Verucchi G "Myocardial infarction risk in HIV-infected patients: epidemiology, pathogenesis,  and clinical management." AIDS 24 (2010): 789-802</p><h2>More about lopinavir / ritonavir</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>4 Reviews</li>
<li>Drug class: protease inhibitors</li>
<li>FDA Alerts (2)</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Lopinavir and ritonavir &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +2 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>HIV Infection</li>
<li>Nonoccupational Exposure</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>